| scholarly article | Q13442814 |
| P50 | author | Gerd Wallukat | Q63288594 |
| Ralf Dechend | Q63812628 | ||
| P2093 | author name string | Babbette LaMarca | |
| Katrin Wenzel | |||
| Michael J Ryan | |||
| James N Martin | |||
| Sydney R Murphy | |||
| Lillian Fournier Ray | |||
| Kathy Cockrell | |||
| Marc Parrish | |||
| Lyndsay Roberts | |||
| Porter Glover | |||
| P2860 | cites work | Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy | Q34182166 |
| Recent Insights into the pathogenesis of pre-eclampsia | Q34682287 | ||
| Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models | Q34691722 | ||
| Potential roles of angiotensin receptor-activating autoantibody in the pathophysiology of preeclampsia | Q35681821 | ||
| Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice | Q35701236 | ||
| Activating auto-antibodies against the AT1 receptor in preeclampsia | Q36010629 | ||
| Role of sex steroids in modulating tumor necrosis factor alpha-induced changes in vascular function and blood pressure | Q36168798 | ||
| Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia | Q36380482 | ||
| Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia | Q37079628 | ||
| Hypertension in response to chronic reductions in uterine perfusion in pregnant rats: effect of tumor necrosis factor-alpha blockade | Q37459545 | ||
| Placental cytokines and the pathogenesis of preeclampsia | Q41452017 | ||
| Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation | Q44218760 | ||
| AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase | Q44385661 | ||
| Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection | Q45259438 | ||
| Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion | Q46877931 | ||
| Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. | Q52940276 | ||
| Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. | Q54661322 | ||
| Hypoxia stimulates cytokine production by villous explants from the human placenta | Q73320161 | ||
| AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor | Q73815485 | ||
| Enhanced vascular reactivity during inhibition of nitric oxide synthesis in pregnant rats | Q74518978 | ||
| Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature | Q81423834 | ||
| An emerging role for inflammatory cytokines in hypertension | Q82508329 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | arterial hypertension | Q41861 |
| autoantibody | Q785022 | ||
| P304 | page(s) | 905-909 | |
| P577 | publication date | 2009-08-24 | |
| P1433 | published in | Hypertension | Q5958695 |
| P1476 | title | Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. | |
| P478 | volume | 54 |
| Q36115311 | A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model |
| Q38246351 | A potential pathophysiological role for galectins and the renin-angiotensin system in preeclampsia |
| Q53700889 | AT1-AA (Angiotensin II Type 1 Receptor Agonistic Autoantibody) Blockade Prevents Preeclamptic Symptoms in Placental Ischemic Rats. |
| Q35994304 | Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats |
| Q37507162 | Administration of interleukin-17 soluble receptor C suppresses TH17 cells, oxidative stress, and hypertension in response to placental ischemia during pregnancy |
| Q33983807 | Advances in the pathophysiology of pre-eclampsia and related podocyte injury |
| Q34541831 | Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor Enhance Angiotensin II-Induced Renal Vascular Sensitivity and Reduce Renal Function During Pregnancy |
| Q34978758 | Agonistic antibody to angiotensin II type 1 receptor accelerates atherosclerosis in ApoE-/- mice |
| Q36355165 | Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia |
| Q47637223 | Alterations in endothelin type B receptor contribute to microvascular dysfunction in women who have had preeclampsia |
| Q36339336 | An increased population of regulatory T cells improves the pathophysiology of placental ischemia in a rat model of preeclampsia |
| Q35576417 | Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction |
| Q36683260 | Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats |
| Q37353499 | Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension |
| Q27027039 | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond |
| Q43939628 | Angiotensin type 1 receptor autoantibody from preeclamptic patients induces human fetoplacental vasoconstriction |
| Q46300987 | Animal models of preeclampsia: translational failings and why. |
| Q28534198 | Antibodies against AT1 receptors are associated with vascular endothelial and smooth muscle function impairment: protective effects of hydroxysafflor yellow A |
| Q50077615 | Autoantibodies against angiotensin and adrenergic receptors: more than a biomarker? |
| Q35715914 | Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia |
| Q33789436 | B cells: the old new players in reproductive immunology |
| Q28083815 | Bioactive factors in uteroplacental and systemic circulation link placental ischemia to generalized vascular dysfunction in hypertensive pregnancy and preeclampsia |
| Q36339273 | Blockade of CD40 ligand for intercellular communication reduces hypertension, placental oxidative stress, and AT1-AA in response to adoptive transfer of CD4+ T lymphocytes from RUPP rats |
| Q33826667 | Cellular localization, expression and functional implications of the utero-placental endothelin system during maintenance and termination of canine gestation |
| Q36850156 | Control of endothelin-a receptor expression by progesterone is enhanced by synergy with Gata2. |
| Q42793596 | Down but not out: an emerging role for the B-type endothelin receptor in placental ischemia-induced hypertension. |
| Q34051646 | Downregulation of microvascular endothelial type B endothelin receptor is a central vascular mechanism in hypertensive pregnancy |
| Q26852668 | Elucidating immune mechanisms causing hypertension during pregnancy |
| Q33577570 | Endothelial dysfunction induced by antibodies against angiotensin AT1 receptor in immunized rats |
| Q37229246 | Endothelial dysfunction. An important mediator in the pathophysiology of hypertension during pre-eclampsia |
| Q36245112 | Endothelin as a final common pathway in the pathophysiology of preeclampsia: therapeutic implications |
| Q34772464 | Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance |
| Q37244292 | Endothelin, kidney disease, and hypertension |
| Q37353537 | Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy |
| Q36073225 | Endothelin: key mediator of hypertension in preeclampsia |
| Q36351174 | Four Pathways Involving Innate Immunity in the Pathogenesis of Preeclampsia |
| Q36380039 | GPCRs as potential therapeutic targets in preeclampsia. |
| Q36268948 | Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy |
| Q37306127 | Gestational hypoxia induces preeclampsia-like symptoms via heightened endothelin-1 signaling in pregnant rats |
| Q36464970 | Homocysteine, endothelin-1 and nitric oxide in patients with hypertensive disorders complicating pregnancy |
| Q83799951 | Hypertension in response to AT1-AA: role of reactive oxygen species in pregnancy-induced hypertension |
| Q36115279 | Hypertension in response to CD4(+) T cells from reduced uterine perfusion pregnant rats is associated with activation of the endothelin-1 system. |
| Q36244980 | Hypertension in response to IL-6 during pregnancy: role of AT1-receptor activation |
| Q35029700 | Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes |
| Q36997267 | IL-10 supplementation increases Tregs and decreases hypertension in the RUPP rat model of preeclampsia |
| Q36178540 | IL-17-mediated oxidative stress is an important stimulator of AT1-AA and hypertension during pregnancy |
| Q53433801 | Identification of a Novel Agonist-Like Autoantibody in Preeclamptic Patients. |
| Q36409599 | Immune Mechanisms Linking Obesity and Preeclampsia |
| Q67405024 | Immune mechanisms of hypertension. |
| Q36422496 | Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms |
| Q49351706 | Inflammatory and Immune System Markers. |
| Q36106483 | Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1. |
| Q38543831 | Linking the old and new -- do angiotensin II type 1 receptor antibodies provide the missing link in the pathophysiology of preeclampsia? |
| Q46342648 | Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia |
| Q36910638 | Matrix metalloproteinases as drug targets in preeclampsia |
| Q37211008 | Mechanisms and potential therapies for preeclampsia |
| Q37136212 | Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia |
| Q58589187 | Molecular Determinants of Microvascular Dysfunction in Hypertensive Pregnancy and Preeclampsia |
| Q33349894 | Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia |
| Q27010670 | New approaches for managing preeclampsia: clues from clinical and basic research |
| Q26865332 | Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology |
| Q37451544 | Placental Ischemia and Resultant Phenotype in Animal Models of Preeclampsia |
| Q34547520 | Placental ischemia induces changes in gene expression in chorionic tissue |
| Q38889590 | Preeclampsia and the brain: neural control of cardiovascular changes during pregnancy and neurological outcomes of preeclampsia |
| Q104137018 | Preeclampsia: Linking Placental Ischemia with Maternal Endothelial and Vascular Dysfunction |
| Q36965155 | Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines |
| Q26800272 | Preeclampsia: long-term consequences for vascular health |
| Q28395340 | Pregnant rats treated with a high-fat/prooxidant Western diet with ANG II and TNF-α are resistant to elevations in blood pressure and renal oxidative stress |
| Q33983395 | Progesterone supplementation attenuates hypertension and the autoantibody to the angiotensin II type I receptor in response to elevated interleukin-6 during pregnancy |
| Q42701351 | Progress toward identifying potential markers for preeclampsia: role of agonistic autoantibody to the angiotensin II type I receptor |
| Q38691672 | Proliferation of endogenous regulatory T cells improve the pathophysiology associated with placental ischaemia of pregnancy |
| Q36537709 | RAS in Pregnancy and Preeclampsia and Eclampsia |
| Q39136791 | Recent Advances in Immunity and Hypertension |
| Q34404445 | Recent insights into the pathophysiology of preeclampsia |
| Q35707881 | Receptor-activating autoantibodies and disease: preeclampsia and beyond |
| Q45848306 | Reduced uterine perfusion pressure T-helper 17 cells cause pathophysiology associated with preeclampsia during pregnancy |
| Q35363716 | Regulation of soluble fms-like tyrosine kinase-1 production in response to placental ischemia/hypoxia: role of angiotensin II. |
| Q92071252 | Renal natural killer cell activation and mitochondrial oxidative stress; new mechanisms in AT1-AA mediated hypertensive pregnancy |
| Q64907090 | Renin-angiotensin system in pre-eclampsia: everything old is new again. |
| Q57167914 | Residual Vascular Dysfunction in Women with a History of Preeclampsia |
| Q47546316 | Role and mechanism of AT1-AA in the pathogenesis of HELLP syndrome |
| Q41653771 | Role of IgM and angiotensin II Type I receptor autoantibodies in local complement activation in placental ischemia-induced hypertension in the rat. |
| Q34785813 | Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia |
| Q26828020 | Role of endothelin in uteroplacental circulation and fetal vascular function |
| Q36767058 | Serum agonistic autoantibodies against type-1 angiotensin II receptor titer in patients with epithelial ovarian cancer: a potential role in tumor cell migration and angiogenesis |
| Q90533738 | Sex differences in redox homeostasis in renal disease |
| Q64935754 | Sex-Specific Contributions of Endothelin to Hypertension. |
| Q52594781 | The Endothelin System: A Critical Player in the Pathophysiology of Preeclampsia. |
| Q37729072 | The Endothelin Type A Receptor as a Potential Therapeutic Target in Preeclampsia |
| Q47577568 | The agonistic autoantibodies to the angiotensin II type 1 receptor in pregnancies complicated by hypertensive disorders |
| Q91910507 | The angiotensin II type I receptor contributes to impaired cerebral blood flow autoregulation caused by placental ischemia in pregnant rats |
| Q36407259 | The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy |
| Q38693025 | The emerging role of endothelin-1 in the pathogenesis of pre-eclampsia |
| Q27003301 | The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin? |
| Q57150158 | The role of Agonistic Autoantibodies to the Angiotensin II Type 1 Receptor (AT1-AA) in Pathophysiology of Preeclampsia |
| Q37088970 | The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia |
| Q38419238 | The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). |
| Q38592484 | Thrombosis during pregnancy: Risks, prevention, and treatment for mother and fetus--harvesting the power of omic technology, biomarkers and in vitro or in vivo models to facilitate the treatment of thrombosis. |
| Q36309225 | Timing of ischemic insult alters fetal growth trajectory, maternal angiogenic balance, and markers of renal oxidative stress in the pregnant rat. |
| Q34114402 | Vaccines in the management of hypertension |
| Q38124456 | Vascular dysfunction in preeclampsia |
| Q36699839 | Vitamin D supplementation improves pathophysiology in a rat model of preeclampsia |
| Q51294484 | Vitamin D supplementation reduces some AT1-AA-induced downstream targets implicated in preeclampsia including hypertension. |
Search more.